Navigation Links
Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001

RESEARCH TRIANGLE PARK, N.C., Jan. 6 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers. This study supports the further development of the drug for multiple dsDNA infections. The Company has initiated the first Phase II multi-dose clinical trial in patients.

"The safety and high oral availability demonstrated by CMX001 in the Phase I trial has exceeded our original expectations," said Dr. George Painter, Chimerix President and CEO. "We believe that CMX001 has potential for prevention and treatment of many serious and potentially fatal infections such as smallpox, cytomegalovirus, BK virus and adenovirus."

The Phase I study of CMX001 was a blinded, randomized, placebo-controlled study that evaluated the safety and pharmacokinetics of orally administered CMX001 in healthy volunteers. The study found CMX001 to be well tolerated at all doses in 84 healthy volunteers.

The first Phase II trial will study the effects of multiple doses of CMX001 given to stem cell and kidney transplant recipients with BK viruria, a condition which may eventually lead to loss of the kidney graft, or to uncontrolled bleeding in the bladder. Further studies are planned to explore the ability of CMX001 to prevent cytomegalovirus disease, a viral disease that may lead to blindness or severe gastrointestinal disease after bone marrow transplant.

CMX001 is being developed for the treatment of smallpox infection and other double stranded DNA virus infections that cause significant human morbidity and mortality. A safe, orally active antiviral drug to treat smallpox infection is needed to help people who become ill after exposure to the disease or those who cannot be vaccinated. The work is partially funded by a $36.1 million grant awarded to the company by the National Institute of Allergy and Infectious Diseases.

About Chimerix

Chimerix, Inc. discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid, prodrug technology, ProLipTag(TM), Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events.

SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
2. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
3. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Carrington Completes $8 Million Financing
7. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
8. New Brunswick Scientific Completes Merger Transaction with Eppendorf
9. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
10. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
11. Optherion, Inc. Completes $37 Million Start Up Financing
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
Breaking Biology News(10 mins):